Semaglutide

Dosing from the Literature

Published for fat loss: Wegovy's 2.4 mg once a week, reached step by step, from the STEP trials. Not published: nothing missing; the dose is on the label.

FDA-approved dosing schedules for branded formulations. All injectable doses are once weekly subcutaneous.

What It Is

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist — a 31-amino-acid peptide analog of the naturally occurring incretin hormone GLP-1(7–37). Developed by Novo Nordisk and first approved by the FDA in 2017, it has become one of the most consequential pharmaceutical developments of the 21st century. The molecule is engineered with three key modifications: an α-aminoisobutyric acid (Aib) substitution at position 8 that confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation, an arginine substitution at position 34, and a C-18 fatty diacid chain attached at position 26 via a linker that binds albumin in the blood. This albumin binding extends the plasma half-life from approximately 2 minutes (native GLP-1) to roughly 7 days, enabling once-weekly dosing.

What makes semaglutide historically significant is that it was the first drug to demonstrate both clinically meaningful sustained weight loss and cardiovascular mortality benefit in large randomized controlled trials. Before semaglutide, no pharmacological intervention for obesity had cleared both of those bars simultaneously. The STEP trial program showed 15–17% body weight reduction at therapeutic doses, and the SELECT trial (n=17,604) demonstrated a 20% reduction in major adverse cardiovascular events in overweight and obese adults without diabetes. These results fundamentally shifted the medical conversation about obesity from a condition of willpower to a condition of biology amenable to pharmacological intervention.

Semaglutide is available in three branded formulations: Ozempic (injectable, approved for type 2 diabetes), Wegovy (injectable, approved for chronic weight management and — as of March 2024 — cardiovascular risk reduction in overweight/obese adults with established CVD), and Rybelsus (oral tablet, approved for type 2 diabetes). All three contain the same semaglutide molecule at different doses and regulatory indications. Compounded semaglutide has also been widely available through 503A and 503B pharmacies through the FDA-declared shortage window, at substantially lower cost than branded formulations.

Mechanism of Action

Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target of the body's own GLP-1 (Ozempic label). This distinguishes it from tirzepatide, which activates both GIP and GLP-1 receptors (Mounjaro label). GLP-1 receptors are found well beyond the pancreas: in the gastrointestinal tract, heart, lungs, kidneys and brain (Knudsen & Lau, 2019; PMID 31031702).

• Pancreatic GLP-1R activation (glucose-dependent insulin secretion) — In β cells, GLP-1 receptor activation raises cAMP, which acts through PKA and Epac2 to amplify insulin release (Müller et al., 2019; PMID 31767182). The labels describe semaglutide's insulin effect as glucose-dependent, with insulin secretion stimulated when blood glucose is high, and tie a higher risk of low blood sugar to use with insulin or a sulfonylurea. Semaglutide also lowers glucagon secretion, in the same glucose-dependent way (Ozempic label).
• Hypothalamic (brain's hormonal control center) appetite regulation (POMC/CART and NPY/AgRP pathways) — In mice, GLP-1 receptors sit in the hypothalamus's arcuate and paraventricular nuclei (Müller et al., 2019; PMID 31767182). In animals, the related drug liraglutide reached POMC/CART neurons there, raised CART and blunted rises in NPY/AgRP, and studies indicate semaglutide gets into the brain more readily than liraglutide (Knudsen & Lau, 2019; PMID 31031702). In a 12-week study in people with obesity, semaglutide cut energy intake over three meals and snacks by an average 24% and reduced food cravings (Knudsen & Lau, 2019). fMRI studies in healthy people and people with type 2 diabetes support a brain-based effect of GLP-1 on eating (Müller et al., 2019).
• Brainstem satiety signaling (NTS and area postrema) — In mice, GLP-1 receptors are found in the hindbrain's nucleus tractus solitarius and area postrema (Müller et al., 2019; PMID 31767182), and in animal studies semaglutide reached and activated neurons in brain regions that regulate food intake (Wegovy label). The area postrema is one of the circumventricular organs that long-acting GLP-1 drugs reach from the blood in mice (Knudsen & Lau, 2019; PMID 31031702); in rats, GLP-1 acting in the brain activates the same hindbrain areas as the nausea-inducing chemical lithium chloride (Müller et al., 2019). Nausea and diarrhea were the most common side effects in STEP 1 (Wilding et al., 2021; PMID 33567185).
• Delayed gastric emptying — Semaglutide causes a minor delay in gastric emptying early after a meal (Ozempic label). Long-acting GLP-1 drugs like semaglutide slow emptying less than short-acting ones, with little effect left at steady state, so slower emptying is unlikely to be how they cut food intake; the authors propose they act on the brain directly rather than mainly through the vagus nerve (Knudsen & Lau, 2019; PMID 31031702).
• Cardiovascular effects (mechanism not established) — How semaglutide lowers cardiovascular risk has not been established (Wegovy label). In the human heart, GLP-1 receptors are limited to the sinoatrial node rather than the heart muscle as a whole, which may explain a small rise in pulse; in atherosclerosis-prone mice, semaglutide shrank aortic plaque independent of weight and lipid changes and damped inflammation-related genes in the artery wall (Knudsen & Lau, 2019; PMID 31031702). In SELECT, major cardiovascular events fell 20% in adults with cardiovascular disease and overweight or obesity but no diabetes (HR 0.80; Lincoff et al., 2023; PMID 37952131).
• Renal effects (natriuresis) — GLP-1 receptor agonists acutely raise sodium excretion in rodents and may do so in humans (Müller et al., 2019; PMID 31767182). In primate and human kidneys, GLP-1 receptors sit only in the smooth muscle of arteries and arterioles, not in the tubules (Knudsen & Lau, 2019; PMID 31031702), and the mechanism behind semaglutide's kidney results has not been established (Ozempic label). In FLOW, 3,533 adults with type 2 diabetes and chronic kidney disease had a 24% lower risk of major kidney disease events on semaglutide 1.0 mg weekly than on placebo (HR 0.76; Perkovic et al., 2024; PMID 38785209).
• Albumin binding and extended pharmacokinetics — A C18 fatty diacid, attached through a spacer to lysine 26, lets semaglutide bind albumin reversibly (Ozempic label; Knudsen & Lau, 2019; PMID 31031702). More than 99% of semaglutide in plasma is albumin-bound, which lowers renal clearance and protects it from breakdown; its elimination half-life is about one week (Wegovy label).
• Liver effects (indirect) — Hepatocytes carry no measurable GLP-1 receptors; in an animal study, semaglutide's benefit in fatty liver appeared indirect, through reduced inflammation (Knudsen & Lau, 2019; PMID 31031702). How it improves MASH in people is not fully understood and may involve weight loss and other pathways; in a mouse model of diet-induced MASH it improved steatosis, inflammation and fibrosis (Wegovy label). Phase 2 data showed significant resolution of steatohepatitis with semaglutide (PMID 33185364).
• Neuroprotective potential (preclinical) — GLP-1 receptors are found in discrete areas of the brain (Knudsen & Lau, 2019; PMID 31031702). In rodent models of Alzheimer's disease, GLP-1 receptor agonists prevented memory deficits (Müller et al., 2019; PMID 31767182). In people, the Phase 3 evoke and evoke+ trials of oral semaglutide 14 mg in 3,808 adults with early Alzheimer's disease did not slow its progression (Novo Nordisk, November 24, 2025).
• GLP-1 selectivity vs dual GLP-1/GIP agonism — Semaglutide selectively activates the GLP-1 receptor (Ozempic label). Tirzepatide activates both GIP and GLP-1 receptors (Mounjaro label); retatrutide, still investigational, adds the glucagon receptor (Eli Lilly, May 2026).

What the Research Shows

Semaglutide has one of the most extensive clinical evidence bases of any drug developed in the past two decades. Multiple large-scale Phase 3 randomized controlled trial programs have established efficacy across obesity, type 2 diabetes, cardiovascular disease, chronic kidney disease, and liver disease.

• Obesity (STEP program) — STEP 1 (n=1,961) demonstrated 14.9% mean body weight loss vs 2.4% with placebo at 68 weeks. STEP 3 showed 16.0% weight loss with intensive behavioral therapy. STEP 5 (104 weeks) demonstrated sustained 15.2% weight loss. STEP 8, a direct comparison against liraglutide 3.0 mg, showed roughly double the weight loss (15.8% vs 6.4%).
• Cardiovascular outcomes (SELECT) — 17,604 overweight or obese adults aged 45+ with established CVD but without diabetes. Semaglutide 2.4 mg weekly reduced the composite primary endpoint of MACE by 20% vs placebo over a median 39.8 months (HR 0.80; PMID 37952131). First cardiovascular mortality benefit for any weight management drug in non-diabetic patients.
• Chronic kidney disease (FLOW) — 3,533 patients with T2D and CKD. Semaglutide 1.0 mg weekly reduced the primary composite kidney endpoint by 24% (HR 0.76; PMID 38785209). Stopped early by DSMB for efficacy.
• Type 2 diabetes (SUSTAIN program) — SUSTAIN 6 (n=3,297) demonstrated 26% reduction in MACE in T2D patients with high CV risk (PMID 27633186). Across the program, semaglutide showed superior HbA1c reduction vs sitagliptin, exenatide, dulaglutide, insulin glargine, and canagliflozin.
• Oral formulation (PIONEER program) — PIONEER 1 showed significant HbA1c reduction with oral semaglutide 14 mg daily vs placebo (PMID 31186300). The oral formulation uses the absorption enhancer SNAC to enable GI uptake despite peptide structure.
• Liver disease (MASH/NASH) — Phase 2 showed semaglutide 0.4 mg daily resolved steatohepatitis in 59% vs 17% with placebo (PMID 33185364). Phase 3 trials are ongoing.
• Alzheimer's disease (EVOKE) — Phase 3 trials of oral semaglutide in early Alzheimer's. Readouts pending.
• Head-to-head vs liraglutide (STEP 8) — Semaglutide 2.4 mg vs liraglutide 3.0 mg; semaglutide achieved 15.8% vs 6.4% body weight reduction at 68 weeks (PMID 35015037).
• Durability (STEP 5) — Two-year data showing sustained weight loss of 15.2% at 104 weeks, confirming durability beyond one year (PMID 36216945).

Human Data

Semaglutide has been studied in over 50 completed randomized controlled trials enrolling tens of thousands of participants. Key landmark trials with specific outcomes:

• STEP 1 (NCT03548935) — 1,961 adults with BMI ≥30 (or ≥27 with comorbidity), no diabetes. Semaglutide 2.4 mg weekly vs placebo for 68 weeks. Primary endpoint: 14.9% mean weight loss vs 2.4% placebo. 86.4% lost ≥5% body weight. 32% lost ≥20%. NEJM 2021 (PMID 33567185).
• STEP 2 (NCT03552757) — 1,210 adults with overweight/obesity and T2D. Semaglutide 2.4 mg weekly achieved 9.6% vs 3.4% placebo at 68 weeks. Lancet 2021 (PMID 33667417).
• STEP 3 (NCT03611582) — 611 adults with overweight/obesity, no diabetes, semaglutide 2.4 mg + intensive behavioral therapy. 16.0% vs 5.7% placebo at 68 weeks. JAMA 2021 (PMID 33625476).
• STEP 4 (NCT03548987) — Continued weekly semaglutide vs placebo for weight-loss maintenance after 20-week run-in. JAMA 2021 (PMID 33755728).
• STEP 5 (NCT03693430) — 304 adults; 104-week data demonstrating sustained −15.2% vs −2.6% placebo, confirming durability. Nat Med 2022 (PMID 36216945).
• STEP 8 (NCT04074161) — 338 adults; head-to-head semaglutide 2.4 mg vs liraglutide 3.0 mg. 15.8% vs 6.4% at 68 weeks. JAMA 2022 (PMID 35015037).
• SELECT (NCT03574597) — 17,604 adults ≥45, BMI ≥27, established CVD, no diabetes. Semaglutide 2.4 mg for median 39.8 months. 20% reduction in 3-point MACE (HR 0.80; PMID 37952131).
• FLOW (NCT03819153) — 3,533 patients with T2D and CKD. Semaglutide 1.0 mg weekly. Primary composite kidney endpoint reduced by 24% (PMID 38785209).
• SUSTAIN 6 (NCT01720446) — 3,297 patients with T2D and high CV risk. Semaglutide 0.5 or 1.0 mg weekly for 104 weeks. 26% reduction in 3-point MACE (PMID 27633186).
• PIONEER 1 (NCT02906930) — Oral semaglutide monotherapy in T2D (PMID 31186300).
• MASH Phase 2 (NCT02970942) — Semaglutide 0.4 mg daily in NASH; 59% histological resolution (PMID 33185364).
• REMODEL (NCT04865770) — 106 adults with type 2 diabetes and chronic kidney disease at 28 sites in 8 countries, randomized 2:1 to semaglutide 1.0 mg weekly or placebo for 52 weeks to identify how it protects the kidney. Its three co-primary MRI measures, kidney oxygenation, perfusion and an inflammation marker, did not differ from placebo. Among secondary measures, renal artery resistance fell and the cortical diffusion coefficient stayed higher, which the authors read as fibrosis not progressing; in paired kidney biopsies, single-cell gene expression (22 people) changed most in glomerular endothelial cells. Albuminuria, an exploratory measure, fell 40% against placebo. Adverse events led 9 of 71 on semaglutide (12.7%) and 1 of 35 on placebo (2.9%) to stop. Funded by Novo Nordisk. Nat Med 2026 (Tuttle et al.; PMID 42823485).
• HD1916, a chemically synthesized semaglutide (Phase 3, China) — 462 Chinese adults aged 18–75 with obesity (BMI 28 or more) and no diabetes, randomized open-label at 30 centres to weekly HD1916 or Wegovy for 44 weeks: weight fell 13.1% on HD1916 and 14.4% on Wegovy, a difference of 1.35 points (95% CI −0.02 to 2.72) inside the trial’s equivalence margin of ±4.16 points; adverse events occurred in 86.5% and 89.2%, most of grade 1–2. Diabetes Obes Metab 2026 (Gao et al.; PMID 42839752; the abstract was read, the full text is paywalled).
• HISTORI (NCT05193578) — 154 adults aged 18–60 in Denmark with schizophrenia-spectrum disorders on second-generation antipsychotics, prediabetes (HbA1c 5.7–6.4%) and a BMI of 27 or more, randomized to semaglutide up to 1.0 mg weekly or placebo for 30 weeks: against placebo, HbA1c fell 0.46 percentage points and weight 9.21 kg, and 81% against 19% ended with an HbA1c below 5.7%; physical quality of life improved, while psychotic symptoms (PANSS-6) and mental quality of life did not change; gastrointestinal symptoms were more frequent on semaglutide, and serious adverse events did not differ (Ganeshalingam et al., JAMA Psychiatry 2025; PMID 40900607). In the trial’s analysis of insulin action, fasting glucose fell 0.87 mmol/L and insulin sensitivity rose against placebo, the gain mediated by weight loss, while β-cell function did not change significantly (Ganeshalingam et al., Diabetes Care 2026; PMID 41778920). Novo Nordisk supplied the drug and the randomization list and, the authors write, was otherwise not involved.

Additional Phase 3 trials are underway or recently completed for MASH/NAFLD, Alzheimer's disease (EVOKE and EVOKE+), heart failure with preserved ejection fraction, and peripheral artery disease.

Reconstitution & Storage

Brand-name semaglutide injections (Ozempic, Wegovy) come as a ready-made solution in prefilled pens or syringes, with nothing to mix (Ozempic and Wegovy labels). The table below is vial arithmetic for compounded semaglutide sold as freeze-dried powder, which seller guides list in vials of 2 to 10 mg; sellers also describe ready-mixed vials, most often 2.5 mg/mL.

• Reconstitution — Seller reconstitution guides describe adding the bacteriostatic water slowly down the inside wall of the vial, then swirling rather than shaking until the powder dissolves, and describe the mixed solution as clear and colorless.
• Storage (reconstituted) — Seller guides list 2–8°C after mixing, out of the light and never frozen, with a 28-day use-by date, and name cloudiness, particles or discoloration as signs not to use it.
• Storage (lyophilized) — One seller's storage guide lists 12–24 months refrigerated for unmixed powder.
• Brand pens (Ozempic/Wegovy) — Ozempic pens and the multi-dose Wegovy FlexTouch pen are refrigerated before first use, then kept up to 56 days at 15–30°C or in the refrigerator. Wegovy single-dose pens and syringes are refrigerated and may be kept at 8–30°C for up to 28 days before the cap comes off. None is frozen (Ozempic and Wegovy labels).
• Injection technique — The labels list subcutaneous injection in the abdomen, thigh or upper arm, rotating the site with each dose (Ozempic and Wegovy labels). Seller guides for compounded vials list U-100 insulin syringes of 27–31 gauge.

→ Calculator — vial-to-syringe math

Side Effects & Risks

In the large trials, the most common adverse events were gastrointestinal (Wilding et al., 2021; Aroda et al., 2019):

• Nausea — 44% on semaglutide 2.4 mg vs 16% on placebo in the three weight-loss trials behind the Wegovy label, reported most often while the dose was being raised (Wegovy label). In STEP 1, nausea and diarrhea were mostly transient and mild to moderate and subsided with time (Wilding et al., 2021).
• GI distress — Diarrhea ~30%, vomiting ~25%, constipation ~24% and abdominal pain ~20% on semaglutide 2.4 mg, vs 16%, 6%, 11% and 10% on placebo. They were the main reason for stopping: 6.8% stopped for adverse reactions vs 3.2% on placebo, most often for nausea, vomiting or diarrhea (Wegovy label).
• Pancreatitis — Rare but serious: in the Wegovy weight-loss trials, acute pancreatitis was confirmed in 4 people on semaglutide (0.2 cases per 100 patient-years) and 1 on placebo. The labels note it has been seen with GLP-1 receptor agonists and direct stopping the drug if pancreatitis is suspected, as with persistent or severe abdominal pain, sometimes radiating to the back (Ozempic and Wegovy labels).
• Thyroid C-cell tumors (boxed warning) — In rodents, semaglutide caused thyroid C-cell tumors; whether it does in humans is unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 (Ozempic and Wegovy labels).
• Gallbladder events — In the adult weight-loss trials, cholelithiasis was reported in 1.6% on semaglutide vs 0.7% on placebo and cholecystitis in 0.6% vs 0.2%. Rapid weight loss raises gallstone risk, but the excess held even after accounting for weight lost (Wegovy label).
• Lean mass loss — Lean mass makes up roughly 25–40% of the weight lost with diet, incretin drugs or bariatric surgery; in the BELIEVE trial's DEXA scans, 71% of the weight lost on semaglutide 2.4 mg over 48 weeks was fat and the rest lean mass (Heymsfield et al., 2026).
• Rebound weight gain — In STEP 4, adults who switched to placebo after 20 weeks on semaglutide regained 6.9% of their body weight over the next 48 weeks, while those who stayed on it lost a further 7.9% (Rubino et al., 2021).
• Mental health — Post-marketing reports of suicidal thoughts led FDA to review the GLP-1 drugs. Its meta-analysis of 91 placebo-controlled trials with 107,910 patients found no increased risk of suicidal thoughts or behavior, or of depression or anxiety, and in January 2026 FDA asked for that warning to be removed from the Wegovy, Saxenda and Zepbound labels (FDA Drug Safety Communication, January 13, 2026).
• WADA status — Not currently on the WADA prohibited list.
• Compounded product purity — In 2023, FDA warned that some compounders were selling salt forms of semaglutide, such as semaglutide sodium and semaglutide acetate, which are different active ingredients from the one in the approved drugs. FDA's advice is to get a prescription and fill it at a state-licensed pharmacy.
• Drug interactions — Semaglutide slows stomach emptying, so the labels flag other oral medicines, especially those with a narrow therapeutic index, for closer monitoring. With semaglutide tablets, levothyroxine exposure rose 33%, while warfarin and an ethinyl estradiol/levonorgestrel contraceptive showed no clinically significant change (Wegovy and Rybelsus labels). With insulin or a sulfonylurea, the labels list a higher risk of low blood sugar and say a lower dose of those drugs may be needed (Ozempic and Wegovy labels).

Bloodwork & Monitoring

What the FDA labels list, and what the trials measured:

• HbA1c and fasting glucose — In people with diabetes, the Wegovy label calls for monitoring blood glucose before and during treatment; change in HbA1c was the primary end point of PIONEER 1 (Aroda et al., 2019).
• Lipid panel — In SELECT, at week 104 triglycerides were 15.6% lower than on placebo, LDL 2.2% lower and HDL 4.2% higher; these were not among the trial's formally tested end points (Wegovy label).
• Liver enzymes (ALT, AST) — In the pediatric weight-loss trial, ALT rose to 5 times the upper limit of normal or more in 3% of teenagers on semaglutide and none on placebo, some with other causes such as gallstones (Wegovy label).
• Kidney function (creatinine, eGFR, UACR) — The labels call for monitoring kidney function in people with side effects that can dehydrate, such as vomiting or diarrhea, especially while the dose is being raised (Ozempic and Wegovy labels). FLOW enrolled people by eGFR and urine albumin-to-creatinine ratio and tracked eGFR decline (Perkovic et al., 2024).
• Thyroid (calcitonin) — The labels call routine calcitonin or thyroid ultrasound monitoring of uncertain value for finding medullary thyroid cancer early, and list a neck mass, trouble swallowing, shortness of breath or persistent hoarseness as possible symptoms of thyroid tumors (Ozempic and Wegovy labels). STEP 5 tracked calcitonin over two years (Garvey et al., 2022).
• Amylase and lipase — In the weight-loss trials, amylase rose 15–16% and lipase 39% on average from baseline, with no such change on placebo; the label calls their significance unknown without other signs of pancreatitis (Wegovy label).
• Inflammatory markers (CRP) — In STEP 5, C-reactive protein fell 56.7% over two years on semaglutide 2.4 mg vs 7.8% on placebo (Garvey et al., 2022).
• Heart rate — The Wegovy label calls for checking resting heart rate at regular intervals; it rose 1–4 beats per minute on average vs placebo in the weight-loss trials (Wegovy label).
• Eyes (diabetic retinopathy) — The labels call for monitoring people with a history of diabetic retinopathy for progression; in a 2-year trial in type 2 diabetes at high cardiovascular risk, retinopathy complications occurred in 3.0% on semaglutide vs 1.8% on placebo (Ozempic label).

Commonly Stacked With

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

People researching semaglutide often also look at these:

Next Steps

References

1. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641.
2. Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155. PMID: 31031702.
3. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. PMID: 31767182.
4. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186.
5. Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732. PMID: 31186300.
6. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185.
7. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PMID: 33667417.
8. Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. PMID: 33625476.
9. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425. PMID: 33755728.
10. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. PMID: 36216945.
11. Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138-150. PMID: 35015037.
12. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131.
13. Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. PMID: 38785209.
14. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PMID: 33185364.
15. Novo Nordisk. Ozempic (semaglutide) injection, for subcutaneous use — Full Prescribing Information. FDA.gov.
16. U.S. Food and Drug Administration. Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy). February 21, 2025. fda.gov/media/185526/download.
17. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
18. FDA. List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (notice). Federal Register, 91 FR 23431–23444, May 1, 2026; FR Doc. 2026-08552; Docket No. FDA-2018-N-3240. federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal. Comment period extended to July 30, 2026: 91 FR 38719, June 26, 2026; FR Doc. 2026-12937. Read October 3, 2026. (Proposes not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list; restates that an outsourcing facility may compound from a bulk ingredient only if it is on that list or the drug is on FDA’s shortage list.)
19. Novo Nordisk. Wegovy (semaglutide) injection and Wegovy (semaglutide) tablets prescribing information. DailyMed set ID ee06186f-2aa3-4990-a760-757579d8f77b (version effective June 18, 2026). dailymed.nlm.nih.gov. Read October 3, 2026.
20. Novo Nordisk. Rybelsus and Ozempic (semaglutide) tablets prescribing information. DailyMed set ID 27f15fac-7d98-4114-a2ec-92494a91da98 (version effective January 30, 2026). dailymed.nlm.nih.gov. Read October 3, 2026.
21. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635-647. PMID: 40544433.
22. Wong G, Garner EM, Srivastava G. Combined GLP-1 Receptor Agonist and Amylin Analogue Pharmacotherapy to Treat Obesity Comorbid With Type 1 Diabetes. JCEM Case Rep. 2023;1(2):luad040. PMID: 37908483.
23. Stewart R, Ezell KM, Bell DS, et al. Case Series of Nizon-Isidor Syndrome by Heterozygous Variants in MED12L With Further Evidence of Mitotic Instability in One Case With Diploid-Triploid Mosaicism. Am J Med Genet A. 2026;200(1):205-214. PMID: 40838347.
24. Heymsfield SB, Aronne LJ, Montgomery P, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial (BELIEVE). Nat Med. 2026;32(3):869-882. PMID: 41772149.
25. Jastreboff AM, Ryan DH, Bays HE, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. N Engl J Med. 2025;393(9):843-857. PMID: 40549887.
26. Chen SY, Telfser AJ, Olzomer EM, Vancuylenberg CS, et al. Beneficial effects of simultaneously targeting calorie intake and calorie efficiency in diet-induced obese mice. Clin Sci (Lond). 2024;138(4):173-187. PMID: 38315575. DOI: 10.1042/CS20231016.
27. Tuttle KR, Bjornstad P, Smith C, Pruijm M, McCown PJ, Hodgin JB, Cherney DZI, et al. Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial. Nat Med. 2026 (published online October 1, 2026). PMID: 42823485. DOI: 10.1038/s41591-026-04674-2. (REMODEL, NCT04865770; open access, full text read.)
28. Gao L, Ma Y, Zhang Q, et al. Efficacy and Safety of Chemically Synthesized Semaglutide Injection (HD1916) for the Treatment of Obesity: A Multicenter, Randomized, Phase III Trial. Diabetes Obes Metab. 2026 (published online October 7, 2026). PMID: 42839752. DOI: 10.1111/dom.71354. (The abstract was read; the full text is paywalled.)
29. Ganeshalingam AA, Uhrenholt N, Arnfred S, Gæde P, Düring S, Stenager EN, Bünger N, Pedersen AK, Bilenberg N, Frystyk J. Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial. JAMA Psychiatry. 2025;82(11):1065-1074. PMID: 40900607. DOI: 10.1001/jamapsychiatry.2025.2332. (NCT05193578; the abstract was read.)
30. Ganeshalingam AA, Uhrenholt N, Arnfred S, Gæde P, Pedersen AK, Bilenberg N, Frystyk J. Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly. Diabetes Care. 2026;49(5):800-807. PMID: 41778920. DOI: 10.2337/dc25-2041. (Full text read.)

Related Research

• LiraglutideDaily GLP-1 Receptor Agonist
• MazdutideDual GLP-1 / Glucagon Receptor Agonist
• OrforglipronOral Non-Peptide GLP-1 Receptor Agonist
• PemvidutideDual GLP-1 / Glucagon Receptor Agonist
• FDA TrackerPCAC voted on 7 of the 12 peptides on July 23–24, 2026; FDA plans a PCAC review of the other 5 before the end of February 2027.
• AmycretinUnimolecular GLP-1 + Amylin Receptor Agonist (zenagamtide)
• BimagrumabActivin Type II Receptor Antibody (tested with semaglutide in BELIEVE)
• EcnoglutideWeekly GLP-1 Receptor Agonist (Approved in China, 2026)
• MariTideGLP-1 Agonist + GIPR Antagonist Antibody-Peptide Conjugate (Amgen)